Drug
Ampreloxetine Dose A
Ampreloxetine Dose A: highest development phase Phase 1, developed by Theravance Biopharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Theravance Biopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ampreloxetine <Dose A> NCT04688632 | Phase 1 | Symptomatic Neurogenic Orthostatic Hypertension |
Latest
No recent events.
Follow Ampreloxetine Dose A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.